MUNICH, Germany | Jan 23, 2007 | Today the biotech company MediGene (Frankfurt, Prime Standard: MDG) announced the initiation of a clinical phase IIa trial of the drug candidate RhuDex® for the treatment of rheumatoid arthritis. The first patient has already received treatment. The placebo-controlled trial is intended to evaluate the compound’s tolerability and to determine the appropriate dosage for a phase II trial to follow. The trial results are expected in the last half of 2007. Upon completion of this trial, which will include 35 patients, a phase II trial with more than 200 patients is scheduled, starting in 2008.RhuDex® is a novel, orally available T cell co-stimulation modulator for the treatment of rheumatoid arthritis. By specifically blocking T-cell activation it reduces the release of inflammatory cytokines involved in this autoimmune disease.

Ageless Remedies Medical Skincare and Apothecary Opens New Medspa ...

A unique combination of medical skincare services and retail product apothecary, Ageless Remedies offers FDA-approved procedures such as anti-aging laser treatments, microdermabrasion, chemical peels, laser hair removal, IPL, vein treatments, as well as Botox and Restylane. .